•  
  •  
  •  
  •  

2026-07-21 22:09:31

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mastek Reports Q1 FY27 Results: Net Profit Rises 15.3% YoY to ₹106.15 Crore; UK & Europe Operations Lead Growth
  • MedPlus Health Services Reports Q1 FY27 Results: Revenue Up 21.8% YoY to ₹1,879.60 Crore; Net Profit Stands at ₹33.17 Crore
  • Anant Raj Board Approves Strategic Demerger to Create Two Focused Independent Listed Companies
  • Coforge Stands Out as an 'Exceptional Performer' in Application Services and Cloud & Infrastructure Services in Whitelane Research's 2026 UK & Ireland IT Sourcing Study
  • Sagility Limited Reports Strong Q1 FY27 Results: Revenue Surges 27.6% YoY to ₹2,024 Crore; PAT Up 73.5%

Keywords Selected:  TentativeApproval

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • NATCO receives Tentative Approval for Olaparib Tablets from the U.S. FDA
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Gland Pharma Ltd receives tentative approval from USFDA
  • Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • Granules Pharmaceuticals Inc. receives FDA tentative approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets
  • Lupin receives tentative approval from U.S. FDA for Siponimod Tablets
  • Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
  • Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
  • Lupin receives tentative approval from U.S. FDA for Amifampridine Tablets
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg
  • Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution

Latest Post

  • Mastek Reports Q1 FY27 Results: Net Profit Rises 15.3% YoY to ₹106.15 Crore; UK & Europe Operations Lead Growth
  • MedPlus Health Services Reports Q1 FY27 Results: Revenue Up 21.8% YoY to ₹1,879.60 Crore; Net Profit Stands at ₹33.17 Crore
  • Anant Raj Board Approves Strategic Demerger to Create Two Focused Independent Listed Companies
  • Coforge Stands Out as an 'Exceptional Performer' in Application Services and Cloud & Infrastructure Services in Whitelane Research's 2026 UK & Ireland IT Sourcing Study
  • Sagility Limited Reports Strong Q1 FY27 Results: Revenue Surges 27.6% YoY to ₹2,024 Crore; PAT Up 73.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025